Kairos Pharma, LTD 10-Q quarterly reports

Kairos Pharma, Ltd. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing research and development activities alongside significant financial challenges and substantial doubt regarding its ability to continue as a going concern.

Kairos Pharma reports a net loss of $1.65 million for Q1 2026 as it continues clinical development of its oncology pipeline.

Kairos Pharma, an early-stage biotech, reported increased net losses in Q3 2025 while securing significant financing to advance its oncology immunotherapy and cell therapy programs.

Kairos Pharma, a clinical-stage biopharmaceutical company, reported significantly increased net losses and cash burn for the first half of 2025, while successfully securing over $3.9 million in new financing.

Kairos Pharma's Q1 2025 report reveals ongoing clinical trials and a recent private financing aimed at advancing its cancer therapeutics.

Kairos Pharma amends executive employment agreements, secures a $30 million equity line of credit, and reports a net loss of $1.623 million for the nine months ended September 30, 2024, while also detailing various financial and operational updates.